Newscast – Page 156 – media

Shire Receives European Approval for Label Extension of FIRAZYR® (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Paediatric Patients

Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in serving patients with rare diseases, announced today that the European Commission (EC) has approved a label extension granting a new indication for FIRAZYR® (icatibant injection), broadening its use to adolescents and children aged 2 years and older, with hereditary angioedema (HAE) caused by C1-esterase-inhibitor (C1-INH) deficiency. FIRAZYR has been approved in the European Union (EU) since 2008 for symptomatic treatment of acute attacks of HAE in adults with C1-INH deficiency.
- Source: finance.yahoo
- 544
- October 30, 2017
EC FIRAZYR® HAE Shire
US FDA finalises new guidelines for medical device development

The US Food and Drug Administration (FDA) has announced new measures to promote medical device innovation and provide patients with fast access to beneficial technologies.
- Source: medicaldevice-network
- 473
- October 30, 2017
FDA medical device
Skin may regulate blood pressure, study finds

When it comes to high blood pressure, a lack of exercise and a poor diet are often the primary suspects. A new study, however, finds that our skin may play a significant role in the development of the condition.
- Source: medicalnewstoday
- 862
- October 27, 2017
heart attacks high blood pressure oxygen Researches stroke
Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG

Biogen (NASDAQ: BIIB) announced that it has increased the profit potential on aducanumab, its Phase 3 investigational treatment for early Alzheimer’s disease, by reducing the potential royalty payment on potential commercial sales of aducanumab to Neurimmune Holding AG. In exchange for a 15 percent reduction in the previously negotiated royalty rates, Biogen agreed to make a one-time $150 million payment to Neurimmune Holding AG.
- Source: media.biogen
- 473
- October 27, 2017
aducanumab Alzheimer's disease Biogen
Not Enough Participants

Patient participation in clinical trials for cancer patients has been in decline. Researchers determine the barriers prohibiting participation.
- Source: medicalnewsbulletin
- 719
- October 27, 2017
cancer Clinical Trials
Drug can dramatically reduce weight of people with obesity

A drug that targets the appetite control system in the brain could bring about significant weight loss in people with clinical obesity, according to new research.
- Source: Sciencedaily
- 665
- October 27, 2017
obesity semaglutide weight loss
Rheumatoid arthritis may raise COPD risk

New research suggests that people with rheumatoid arthritis are more likely to develop chronic obstructive pulmonary disease (COPD), which is a group of lung diseases that damage the airways and cause problems with breathing.
- Source: medicalnewstoday
- 557
- October 27, 2017
COPD Researches rheumatoid arthritis
Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment of Hemophilia A

Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced the U.S. Food and Drug Administration (FDA) awarded Orphan Drug Designation(ODD) to Shire`s gene therapy candidate SHP654 (also designated as BAX 888), an investigational factor VIII (FVIII) gene therapy for the treatment of hemophilia A. The regulatory agency also granted Shire investigational new drug (IND) status for SHP654.
- Source: finance.yahoo
- 469
- October 27, 2017
FDA hemophilia A Orphan Drug Designation Shire
Brain Studies Now Considered Clinical Trials by NIH

The NIH has amended its definition of clinical trials to include brain studies, introducing new regulations considered unnecessary by many researchers.
- Source: medicalnewsbulletin
- 682
- October 27, 2017
brain Clinical Trials NIH
Handheld spectral analyzer turns smartphone into diagnostic tool

Researchers at the University of Illinois at Urbana-Champaign have developed technology that enables a smartphone to perform lab-grade medical diagnostic tests that typically require large, expensive instruments. Costing only $550, the spectral transmission-reflectance-intensity (TRI)-Analyzer from Bioengineering and Electrical & Computer Engineering Professor Brian Cunningham’s lab attaches to a smartphone and analyzes patient blood, urine, or saliva samples as reliably as clinic-based instruments that cost thousands of dollars.
- Source: Bioengineering;
- 628
- October 26, 2017
diagnostics Researches TRI-Analyzer

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.